Ascend Advanced Therapies’ Post

Is telitacicept effective and safe in patients with SLE who have an inadequate response with belimumab? Find out in our latest article 👉 https://loom.ly/9vZ_-aE #MedEd #lupus

More good news regarding Petosemtamab in HNSCC

Did you know? 1 in 4 households in America has a member with migraine. Explore gammaCore nVNS for your patients, a clinically proven device for effective migraine management. Learn more: https://ow.ly/7IAq50QvH4X #Migraine #electroCore #DidYouKnow For Indications and Safety Information: https://ow.ly/LVGp50QvH51

C-Life CBM-IUI Cell-Bank-Medculture Individual-Universal-Immunotherapy Natural-Ex-Vivo-Accelerated-Supplementation Eliminate-Regenerate-Virus-Bacteria-Cancer-Aging Antigens-Antibodies-mRNAs-Immune-Stromal-Cells Small25cm-Large2.5m-Tissue-Organ-Body-Culture https://lnkd.in/e2S8NFEK

Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV

Is enpatoran well tolerated in patients with active SLE/CLE? Learn more from our recently published summary of findings from a phase Ib trial of enpatoran. 👉 https://loom.ly/-J_HVvM #MedEd #SLE #lupus

The Advanced Therapy Week in #Miami is coming to an end. Many thanks to all our partners for connecting, interesting discussions and great exchange about cell and gene therapies. 🗣👏   #optima #wecareforpeople #packaging #cellandgene #advancedtherapies

Last week in our in vivo #GeneTherapy Discussion Team calls we had some fantastic sharing of experience relating to #rcAAV specifications and analysis. A fascinating topic which has spawned an associated benchmarking survey and is currently with our members for response. The results of the discussion, combined with the benchmarking survey results promises to provide a solid foundation for future #collaboration on the topic of rcAAV. #biophorum

We can help you optimize your health and get you back in the game! #trt #lowT #ed #semaglutide #tirzepatide #getbackinthegame

The AVOID Trial - Some key takeaways; ▪ Indocyanine Green (ICG) use demonstrated significant improvement in leak rates for left-sided colectomy ▪ This phase III trial of 900+ patients showed a 5.2% reduction in anastomotic leak rates when ICG was used for left sided colectomy ▪ A leak rate of 12.8% was present in patients in non-ICG group v’s 7.6% when ICG was used in left sided colectomy group ▪ Patients who underwent rectosigmoid resection showed a 6.1% lower 90-day AL rate (FGBA group 8.6% V’s CBA group 14.7%) https://lnkd.in/eybbutf3 #avoidtrial #avoid #leftsidecolectomy #colorectalsurgery #betterpatientoutcomes #impactofseeingmore #icg #indocyaninegreen #verdye #greenlightleiden #diagnosticgreen